Adnan H Siddiqui1, Robert Zivadinov1, Ralph H B Benedict2, Yuval Karmon2, Jihnhee Yu2, Mary L Hartney2, Karen L Marr2, Vesela Valnarov2, Cheryl L Kennedy2, Murali Ramanathan2, Deepa P Ramasamy2, Kresimir Dolic2, David W Hojnacki2, Ellen Carl2, Elad I Levy2, L Nelson Hopkins2, Bianca Weinstock-Guttman2. 1. From the Departments of Neurosurgery and Radiology, The Jacobs Neurological Institute (A.H.S., Y.K., M.L.H., E.I.L., L.N.H.), and the Departments of Neurology (R.Z., R.H.B.B., D.W.H., B.W.-G.), Biostatistics (J.Y.), and Pharmaceutical Sciences (M.R.), University at Buffalo, State University of New York; and the Buffalo Neuroimaging Analysis Center (R.Z., K.L.M., V.V., C.L.K., D.P.R., K.D., E.C.), NY. asiddiqui@ubns.com rzivadinov@bnac.net. 2. From the Departments of Neurosurgery and Radiology, The Jacobs Neurological Institute (A.H.S., Y.K., M.L.H., E.I.L., L.N.H.), and the Departments of Neurology (R.Z., R.H.B.B., D.W.H., B.W.-G.), Biostatistics (J.Y.), and Pharmaceutical Sciences (M.R.), University at Buffalo, State University of New York; and the Buffalo Neuroimaging Analysis Center (R.Z., K.L.M., V.V., C.L.K., D.P.R., K.D., E.C.), NY.
Abstract
OBJECTIVE: We report the results of the investigation of safety and efficacy of venous angioplasty in patients with multiple sclerosis (MS) with findings of extracranial venous anomalies, considered hallmarks of chronic cerebrospinal venous insufficiency (CCSVI), in a 2-phase study (ClinicalTrials.gov NCT01450072). METHODS: Phase 1 was an open-label safety study (10 patients); phase 2 was sham-controlled, randomized, and double-blind (10 sham procedure, 9 treated). All study patients fulfilled venous hemodynamic screening criteria indicative of CCSVI. Assessment was at 1, 3, and 6 months postprocedure with MRI, clinical, and hemodynamic outcomes. Primary endpoints were safety at 24 hours and 1 month, venous outflow restoration >75% at 1 month, and effect of angioplasty on new lesion activity and relapse rate over 6 months. Secondary endpoints included changes in disability, brain volume, cognitive tests, and quality of life. RESULTS: No perioperative complications were noted; however, one patient with history of syncope was diagnosed with episodic bradycardia requiring placement of a pacemaker before discharge. Doppler evidence-based venous hemodynamic insufficiency severity score (VHISS) was reduced >75% compared to baseline in phase 1 (at 1 month) but not phase 2. In phase 2, higher MRI activity (cumulative number of new contrast-enhancing lesions [19 vs 3, p = 0.062] and new T2 lesions [17 vs 3, p = 0.066]) and relapse activity (4 vs 1, p = 0.389) were identified as nonsignificant trends in the treated vs sham arm over 6 months. Using analysis of covariance, significant cumulative new T2 lesions were related to larger VHISS decrease (p = 0.028) and angioplasty (p = 0.01) over the follow-up. No differences in other endpoints were detected. CONCLUSION:Venous angioplasty is not an effective treatment for MS over the short term and may exacerbate underlying disease activity. CLASSIFICATION OF EVIDENCE: This is a Class I study demonstrating that clinical and imaging outcomes are no better or worse in patients with MS identified with venous outflow restriction who receivevenous angioplasty compared to sham controls who do not receive angioplasty. This study also includes a Class IV phase 1 study of safety in 10 patients receiving the angioplasty procedure.
RCT Entities:
OBJECTIVE: We report the results of the investigation of safety and efficacy of venous angioplasty in patients with multiple sclerosis (MS) with findings of extracranial venous anomalies, considered hallmarks of chronic cerebrospinal venous insufficiency (CCSVI), in a 2-phase study (ClinicalTrials.gov NCT01450072). METHODS: Phase 1 was an open-label safety study (10 patients); phase 2 was sham-controlled, randomized, and double-blind (10 sham procedure, 9 treated). All study patients fulfilled venous hemodynamic screening criteria indicative of CCSVI. Assessment was at 1, 3, and 6 months postprocedure with MRI, clinical, and hemodynamic outcomes. Primary endpoints were safety at 24 hours and 1 month, venous outflow restoration >75% at 1 month, and effect of angioplasty on new lesion activity and relapse rate over 6 months. Secondary endpoints included changes in disability, brain volume, cognitive tests, and quality of life. RESULTS: No perioperative complications were noted; however, one patient with history of syncope was diagnosed with episodic bradycardia requiring placement of a pacemaker before discharge. Doppler evidence-based venous hemodynamic insufficiency severity score (VHISS) was reduced >75% compared to baseline in phase 1 (at 1 month) but not phase 2. In phase 2, higher MRI activity (cumulative number of new contrast-enhancing lesions [19 vs 3, p = 0.062] and new T2 lesions [17 vs 3, p = 0.066]) and relapse activity (4 vs 1, p = 0.389) were identified as nonsignificant trends in the treated vs sham arm over 6 months. Using analysis of covariance, significant cumulative new T2 lesions were related to larger VHISS decrease (p = 0.028) and angioplasty (p = 0.01) over the follow-up. No differences in other endpoints were detected. CONCLUSION:Venous angioplasty is not an effective treatment for MS over the short term and may exacerbate underlying disease activity. CLASSIFICATION OF EVIDENCE: This is a Class I study demonstrating that clinical and imaging outcomes are no better or worse in patients with MS identified with venous outflow restriction who receive venous angioplasty compared to sham controls who do not receive angioplasty. This study also includes a Class IV phase 1 study of safety in 10 patients receiving the angioplasty procedure.
Authors: Elliot M Frohman; Gary Cutter; Gina Remington; Hongjiang Gao; Howard Rossman; Bianca Weinstock-Guttman; Jacqueline E Durfee; Amy Conger; Ellen Carl; Katherine Treadaway; Eric Lindzen; Amber Salter; Teresa C Frohman; Anjali Shah; Angela Bates; Jennifer L Cox; Michael G Dwyer; Olaf Stüve; Benjamin M Greenberg; Michael K Racke; Robert Zivadinov Journal: Ther Adv Neurol Disord Date: 2010-01 Impact factor: 6.570
Authors: Anthony L Traboulsee; Katherine B Knox; Lindsay Machan; Yinshan Zhao; Irene Yee; Alexander Rauscher; Darren Klass; Peter Szkup; Robert Otani; David Kopriva; Shanti Lala; David K Li; Dessa Sadovnick Journal: Lancet Date: 2013-10-09 Impact factor: 79.321
Authors: Kenneth D Mandato; Paul F Hegener; Gary P Siskin; Ziv J Haskal; Meridith J Englander; Sreenivas Garla; Nancy Mitchell; Laura Reutzel; Christopher Doti Journal: J Vasc Interv Radiol Date: 2011-11-15 Impact factor: 3.464
Authors: Andrew D Barreto; Staley A Brod; Thanh-Tung Bui; James R Jemelka; Larry A Kramer; Kelly Ton; Alan M Cohen; John W Lindsey; Flavia Nelson; Ponnada A Narayana; Jerry S Wolinsky Journal: Ann Neurol Date: 2013-02-26 Impact factor: 10.422